Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fabbri

Showing results (11-20 of 570) with videos related to

Pageof 57
Sort By:
Respiratory Medicine|February 21, 2012
Spirometric inclusion criteria of COPD patients in randomized clinical trialsLeonardo M Fabbri
Progress in Biochemical Pharmacology|January 1, 1985
Airway inflammation and asthma. Importance of arachidonate metabolites for airway hyperresponsivenessL M Fabbri
Chest|May 5, 2011
FEV(1)/FVC fixed ratio again!Leonardo M Fabbri
The Journal of Allergy and Clinical Immunology|February 1, 1991
Inhalational challenge reactions to isocyanatesL M Fabbri
The Lancet. Respiratory Medicine|October 13, 2014
Benralizumab: for asthma, not yet for COPDLeonardo M Fabbri
Professioni Infermieristiche|August 24, 1999
[Employment conditions for graduate nurses in the province of Ravenna from 1994-96]S Cifiello, M Fabbri
Tumori|January 5, 2002
[Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial]D Amadori, M Fabbri
Clinical Pharmacology and Therapeutics|February 15, 2016
MicroRNAs and cancer resistance: A new molecular plotF Fanini, M Fabbri
Sarcoidosis|September 1, 1989
Fatal asthmaL M Fabbri, M Saetta
Annali Dell'Istituto Superiore Di Sanita|April 22, 2004
[Chronic obstructive pulmonary disease: definition and classification of severity]Micaela Romagnoli, Leonardo M Fabbri
Pageof 57

Showing results (11-20 of 570) with videos related to

Sort By:
Pageof 57
Respiratory Medicine|February 21, 2012
Spirometric inclusion criteria of COPD patients in randomized clinical trialsLeonardo M Fabbri
Progress in Biochemical Pharmacology|January 1, 1985
Airway inflammation and asthma. Importance of arachidonate metabolites for airway hyperresponsivenessL M Fabbri
Chest|May 5, 2011
FEV(1)/FVC fixed ratio again!Leonardo M Fabbri
The Journal of Allergy and Clinical Immunology|February 1, 1991
Inhalational challenge reactions to isocyanatesL M Fabbri
The Lancet. Respiratory Medicine|October 13, 2014
Benralizumab: for asthma, not yet for COPDLeonardo M Fabbri
Professioni Infermieristiche|August 24, 1999
[Employment conditions for graduate nurses in the province of Ravenna from 1994-96]S Cifiello, M Fabbri
Tumori|January 5, 2002
[Doxorubicin and paclitaxel versus 5-fluorouracil, doxorubicin and cyclophosphamide as first-line treatment in women with metastatic breast carcinoma: final results of a phase III multicenter randomized trial]D Amadori, M Fabbri
Clinical Pharmacology and Therapeutics|February 15, 2016
MicroRNAs and cancer resistance: A new molecular plotF Fanini, M Fabbri
Sarcoidosis|September 1, 1989
Fatal asthmaL M Fabbri, M Saetta
Annali Dell'Istituto Superiore Di Sanita|April 22, 2004
[Chronic obstructive pulmonary disease: definition and classification of severity]Micaela Romagnoli, Leonardo M Fabbri
Pageof 57